Researchers have identified a promising new blood test that may help detect colorectal cancer using a specialized protein called SubB2M to measure a sugar molecule known as Neu5Gc.
The test addresses limitations of current screening methods. Colonoscopies are effective but invasive, while stool-based tests can miss early disease. Existing blood markers such as CEA and CA 19-9 are mainly used for monitoring cancer after diagnosis rather than early detection.
In a study of 120 patients, Neu5Gc levels were significantly higher in colorectal cancer patients at all stages, including early-stage disease. The test showed high accuracy, with strong sensitivity and good specificity, and performed especially well in women. Researchers say this approach could lead to a simple, minimally invasive blood test for earlier and more reliable colorectal cancer screening, with further studies planned to refine its accuracy.